Comparing Dexmedetomidine Versus Magnesium Sulphate Added to Bupivacaine for Pain Relief in Laparoscopic Gallbladder Surgery

What this Trial Is About

Researchers are comparing two adjuvants, dexmedetomidine and magnesium sulphate, added to bupivacaine for pain relief during laparoscopic cholecystectomy, a common minimally invasive gallbladder surgery. While both agents have shown potential to improve analgesia, direct comparisons of their effects when delivered intraperitoneally during this surgery are limited. This study aims to assess their relative effectiveness and safety to help optimize postoperative pain management. Participants will receive intraperitoneal instillation of bupivacaine combined either with dexmedetomidine or magnesium sulphate at the end of surgery before trocar removal. Both groups receive a total volume of 50 mL adjusted with saline. Standard anesthesia and perioperative care will be provided, including intravenous medications and monitoring. The study is randomized, double-blind, and controlled, with two groups receiving either bupivacaine plus dexmedetomidine or bupivacaine plus magnesium sulphate. During the trial, patients will be closely monitored for pain using the Visual Analog Scale at multiple time points up to 24 hours after surgery, quality of recovery via questionnaire, opioid consumption, time to first analgesic request, incidence of nausea and vomiting, and vital signs. Safety and adverse events related to the study drugs will also be recorded. The study is conducted at a tertiary hospital with thorough preoperative evaluation and postoperative pain management, aiming for comprehensive assessment within the first postoperative day.

Intraperitoneal Dexmedetomidine Versus Magnesium as Adjuvants to Bupivacaine in Laparoscopic Cholecystectomy